Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Aug 25, 2013 in Breast cancer | 0 comments

In a nutshell

This study examined whether tamoxifen (nolvadex) can reduce the risk of contralateral breast cancer in women diagnosed with breast cancer and the BRCA1 or BRCA2 genetic mutation.

Some background

The BRCA1 and BRCA2 genetic mutations are associated with a high risk of developing breast cancer. While prophylactic mastectomies (a preventive removal of the breasts) can reduce the risk of developing breast cancer, most women choose not to receive this operation.

Tamoxifen is a drug that blocks the stimulating effects of the hormone estrogen on the growth of cancer cells. For women diagnosed with breast cancer that responds to estrogen (called estrogen receptor positive breast cancer), tamoxifen is known to reduce the risk of developing contralateral breast cancer (cancer in the opposite breast). However, it is not known if tamoxifen can benefit women with BRCA genetic mutations as well.

Methods & findings

This study examined the records of 2464 women diagnosed with unilateral breast cancer (cancer in a single breast) and carrying either the BRCA1 or BRCA2 mutation. 1,583 patients carried the BRCA1 mutation and 881 patients carried the BRCA2 mutation. 383 (24%) of the women in the BRCA1 group and 454 (52%) of the women in the BRCA2 group received tamoxifen after breast cancer diagnosis.

Over the course of the study, 520 cases of contralateral breast cancer were found.  Tamoxifen was found to lower the risk of contralateral breast cancer in women with the BRCA1 mutation by 62%, and in women with the BRCA2 mutation by 67%. Interestingly enough, tamoxifen reduced the risk of contralateral breast cancer regardless of estrogen receptor status (whether the cancer was estrogen receptor positive or estrogen receptor negative).

The bottom line

In summary, tamoxifen was shown to reduce the risk of developing contralateral breast cancer in women carrying the BRCA1 or BRCA2 genetic mutation, regardless of estrogen receptor status.

What’s next?

Consult with your physician regarding treatments that may reduce the risk of developing contralateral breast cancer.

Published By :

Journal of clinical oncology

Date :

Aug 05, 2013

Original Title :

Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.

click here to get personalized updates